Indeed, molecular subtype seems predictive of response to HER2-targeting therapy in general, since the patients who received single HER2-blockade treatment with trastuzumab only and have a HER2-type tumor also have better pCR rates than patients with other tumor subtypes. This evidence concerns the gene ERBB2 and neoplasm.